Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

BACKGROUND: Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Immunother Cancer
Hoofdauteurs: Ressler, Julia Maria, Karasek, Matthias, Koch, Lukas, Silmbrod, Rita, Mangana, Joanna, Latifyan, Sofiya, Aedo-Lopez, Veronica, Kehrer, Helmut, Weihsengruber, Felix, Koelblinger, Peter, Posch, Christian, Kofler, Julian, Michielin, Olivier, Richtig, Erika, Hafner, Christine, Hoeller, Christoph
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2021
Onderwerpen:
Oncolytic and Local Immunotherapy
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7898852/
https://ncbi.nlm.nih.gov/pubmed/33608376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001701
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items